ArticleNeuropsychiatric disease and treatment2019
Association between IL-6 and metabolic syndrome in schizophrenia patients treated with second-generation antipsychotics.
Article in Neuropsychiatric disease and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Prevalence and predictors of metabolic syndrome among psychiatric patients receiving antipsychotic treatment in Africa: a systematic review and meta-analysis.BMC psychiatry · 2025Pooled it
- Effects of IL-6/IL-6R axis alterations in serum, plasma and cerebrospinal fluid with the schizophrenia: an updated review and meta-analysis of 58 studies.Molecular and cellular biochemistry · 2024Pooled it
- The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.Molecular psychiatry · 2022Pooled it
- Use of the RBANS to Evaluate Cognition in Patients with Schizophrenia and Metabolic Syndrome: a Meta-Analysis of Case-Control Studies.The Psychiatric quarterly · 2022Pooled it
- Do proinflammatory cytokines play a role in clozapine-associated glycometabolism disorders?Psychopharmacology · 2021Trial
- Exploring the intricate interplay between metabolic abnormalities and multidimensional cognitive impairment in stable schizophrenia patients.Translational psychiatry · 2026Observational
- Comparing metabolic syndrome parameters, oxidative stress, cellular metabolism, and gene polymorphism between people with schizophrenia and healthy controls.Frontiers in psychiatry · 2026Article
- Drug-Induced Glucose Metabolism Disorders: Role of Aryl Hydrocarbon Receptor.Journal of xenobiotics · 2025Review
- Metabolic Side Effects from Antipsychotic Treatment with Clozapine Linked to Aryl Hydrocarbon Receptor (AhR) Activation.Biomedicines · 2024Review
- Association of obesity to reaction time and visual memory in schizophrenia.Schizophrenia research. Cognition · 2024Article
- Sex differences in the association between metabolic disorder and inflammatory cytokines in Han Chinese patients with chronic schizophrenia.Frontiers in psychiatry · 2024Article
- Serum Interleukin-6 in Schizophrenia: Associations with Clinical and Sociodemographic Characteristics.Consortium psychiatricum · 2023Article
- Low-dose lithium adjunct to atypical antipsychotic treatment nearly improved cognitive impairment, deteriorated the gray-matter volume, and decreased the interleukin-6 level in drug-naive patients with first schizophrenia symptoms: a follow-up pilot study.Schizophrenia (Heidelberg, Germany) · 2023Article
- Sex differences in the association of treatment-resistant schizophrenia and serum interleukin-6 levels.BMC psychiatry · 2023Article
- Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study.CNS neuroscience & therapeutics · 2022Article
- Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine.Psychopharmacology · 2022Article
- Gut Microbial Dysbiosis and Cognitive Impairment in Bipolar Disorder: Current Evidence.Frontiers in pharmacology · 2022Review
- Association Between SIRT1, Cytokines, and Metabolic Syndrome in Schizophrenia Patients With Olanzapine or Clozapine Monotherapy.Frontiers in psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSecond-generation antipsychotics (SGAs) have a high risk of causing metabolic syndrome (MetS). There is accumulating evidence supporting the fact that the activation of inflammatory pathway contributes to the development of MetS and further aggravates cognitive impairment. This study aimed to investigate the relationship between interleukin-6 (IL-6), cognitive function, and MetS in schizophrenia patients treated with SGAs.
methodsOne hundred and seventy-four patients with schizophrenia using SGAs were divided into MetS and non-MetS group, based on the criteria of the National Cholesterol Education Program's Adult Treatment Panel III. Cognitive function was measured using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). A total of 138 patients and 29 healthy controls were examined in the plasma IL-6 levels.
resultsThe prevalence of MetS in schizophrenia patients treated with SGAs was 33% in this study. There were no significant differences in cognitive functions (both RBANS total score and subscale score) between MetS and non-Mets patients (
conclusionOur findings provide evidence suggesting that the immune-inflammatory effect of IL-6 on SGAs-induced MetS may be in a gender manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.